Profile
| Metric | Value |
|---|---|
| Full Name | ADMA Biologics, Inc. |
| Ticker | NASDAQ: ADMA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | admabiologics.com |
| Employees | 685 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $17.93 | |
| Price, 1D Change | -0.11% | |
| Market Cap | $4B | |
| - | ||
| PE Ratio | 21.06 | |
| Beta | 1.12 | |
| Revenue | $426M | |
| Revenue, 1Y Change | +65.15% | |
| EPS | $0.81 | |
| EPS, 1Y Change | +744.17% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $0.81 | |
| EPS Estimate | $0.60 | |
| EPS Est. Change | -26.14% | |
| Revenue | $426.45M | |
| Revenue Estimate | $510.85M | |
| Revenue Est. Change | +19.79% | |
| Current Price | $17.93 | |
| Price Target | - | $30.00 |
| Price Tgt. Change | - | +67.32% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.02 | -$0.13 | -530.50% | |
| $0.52 | $0.81 | +57.73% | |
| $0.60 | N/A | -26.14% | |
| $0.94 | N/A | +15.72% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $256.45M | $258.22M | +0.69% | |
| $422.52M | $426.45M | +0.93% | |
| $510.85M | N/A | +19.79% | |
| $631.85M | N/A | +48.16% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -3.39% | |
| Price, 3Y | +410.83% | |
| Market Cap, 1Y | -2.83% | |
| Market Cap, 3Y | +448.09% | |
| Revenue, 1Y | +65.15% | |
| Revenue, 3Y | +426.86% | |
| EPS, 1Y | +744.17% | |
| EPS, 3Y | +258.25% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $17.93 | |
| SMA 200 | $18.14 | |
| SMA 200 vs Price | +1.15% | |
| SMA 50 | $17.89 | |
| SMA 50 vs Price | -0.25% | |
| Beta | 1.12 | |
| ATR | $0.75 | |
| 14-Day RSI | 43.51 | |
| 10-Day Volatility | 34.47% | |
| 1-Year Volatility | 51.38% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $426.45M | |
| EPS | $0.81 | |
| Gross Profit | $219.17M | |
| Gross Margin | 51.39% | |
| Operating Profit | $138.98M | |
| Operating Margin | 32.59% | |
| Net Income | $197.67M | |
| Net Margin | 46.35% | |
| EBITDA | $147.03M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.24 | |
| Current Ratio | 5.97 | |
| Quick Ratio | 2.90 | |
| - | ||
| F-Score | 6 | |
| Altman Z-Score | 18.72 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 21.06 | |
| PS Ratio | 8.73 | |
| PB Ratio | 9.90 | |
| EV/EBITDA | 24.51 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $349.02M | |
| Cash & Equivalents | $103.15M | |
| Total Assets | $498.38M | |
| Current Assets | $331.41M | |
| Total Liabilities | $149.36M | |
| Current Liabilities | $55.54M | |
| Total Debt | $82.12M | |
| Short Term Debt | $1.22M | |
| Accounts Payable | $20.22M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $228.78M | |
| Operating Expenses | $80.18M | |
| Cost Of Goods Sold | $207.29M | |
| SG&A | $0.00 | |
| D&A | $8.05M | |
| Interest Expense | $0.00 | |
| Income Tax | -$71.96M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $118.67M | |
| CFI | -$8.58M | |
| CFF | -$58.30M | |
| Capex | $8.58M | |
| Free Cash Flow | $110.10M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Raymond James | → | |
| Cantor Fitzgerald | → | |
| Raymond James | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Cantor Fitzgerald | → | |
| HC Wainwright & Co. | → | |
| Cantor Fitzgerald | → | |
| Cantor Fitzgerald | → | |
| Mizuho | → |
Analyst sentiment
Institutional ownership
Screeners with ADMA
Data Sources & References
- ADMA Official Website www.admabiologics.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1368514/000114036125040578/0001140361-25-040578-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1368514/000114036125009257/0001140361-25-009257-index.htm
- ADMA Profile on Yahoo Finance finance.yahoo.com/quote/ADMA
- ADMA Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/adma
FAQ
What is the ticker symbol for ADMA Biologics, Inc.?
The ticker symbol for ADMA Biologics, Inc. is NASDAQ:ADMA
Does ADMA Biologics, Inc. pay dividends?
No, ADMA Biologics, Inc. does not pay dividends
What sector is ADMA Biologics, Inc. in?
ADMA Biologics, Inc. is in the Healthcare sector
What industry is ADMA Biologics, Inc. in?
ADMA Biologics, Inc. is in the Biotechnology industry
What country is ADMA Biologics, Inc. based in?
ADMA Biologics, Inc. is headquartered in United States
When did ADMA Biologics, Inc. go public?
ADMA Biologics, Inc. initial public offering (IPO) was on October 17, 2013
Is ADMA Biologics, Inc. in the S&P 500?
No, ADMA Biologics, Inc. is not included in the S&P 500 index
Is ADMA Biologics, Inc. in the NASDAQ 100?
No, ADMA Biologics, Inc. is not included in the NASDAQ 100 index
Is ADMA Biologics, Inc. in the Dow Jones?
No, ADMA Biologics, Inc. is not included in the Dow Jones index
When was ADMA Biologics, Inc. last earnings report?
ADMA Biologics, Inc.'s most recent earnings report was on November 5, 2025
When does ADMA Biologics, Inc. report earnings?
The next expected earnings date for ADMA Biologics, Inc. is March 2, 2026